researchers are exploring a magl targeted protac degrader that enhances p53 for the treatment of glioblastoma stem cells. the role of various cellular mechanisms, including ars2/magl signaling and grp78 blockade, in glioblastoma is being investigated. other potential therapeutic targets, such as mdm2 and monoacylglycerol lipase, are also being studied for their potential to treat glioblastoma and other cancers.